Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause

Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s

Bayer Q1 2024 net income drops 8.2% to € 2 billion

EBITDA before special items falls 1.3 percent to € 4.41 billion

Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr

Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024

Strides receives USFDA approval for Sevelamer Carbonate Tablets

Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment

Sumitomo Corporation makes full-scale entry into private clinic business in fast-growing southeast Asia

Investing in Malaysia's largest clinic operator to expand the healthcare business

Wipro to implement Independent Health’s Medicare prescription payment plan platform

Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions

Novartis to acquire Mariana Oncology for upfront US$ 1 billion

Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications